Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma.
OBJECTIVE
The activity of carboplatin was evaluated in a phase II window study in previously untreated children with metastatic soft tissue sarcoma.


METHODS
Children with poor-risk metastatic disease (over 10 years and/or with bone/bone marrow involvement) treated in the SIOP MMT 98 study were scheduled to receive two courses of intravenous carboplatin (area under curve [AUC] of 10), 21 days apart.


RESULTS
Sixteen eligible patients were entered into the rhabdomyosarcoma (RMS) group. Response (complete remission or partial remission) was seen in five children (31%, 95% confidence interval (CI) 14-56%). Ten eligible patients with other soft tissue sarcomas were recruited into the non-RMS group. Two responses (20%, 95% CI 6-51%) were seen. Toxicity in both groups was predictable nausea, vomiting and marrow suppression and there were no toxic deaths.


CONCLUSIONS
Single-agent carboplatin at AUC of 10 has an acceptable toxicity profile but only moderate efficacy in poor-risk metastatic soft tissue sarcoma.
Chisholm
J C
JC
Department of Haematology and Oncology, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, UK. chishj@gosh.nhs.uk
Machin
D
D
McDowell
H
H
McHugh
K
K
Ellershaw
C
C
Jenney
M
M
Foot
A B M
AB
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019046:Bone Marrow Neoplasms / Q000556:secondary; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000556:secondary; D012307:Risk Factors; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016190:Carboplatin